the universal pill
DESCRIPTION
The Universal Pill. IGEM Presentation 17 th July 09 James Field Dineka Khurmi Nuri Purswani Kun Xue. Project Description. Problem for oral delivery of peptides 1 pill = 1 drug High manufacturing cost Variable peptide half life Solution… User defined drug production…. - PowerPoint PPT PresentationTRANSCRIPT
![Page 1: The Universal Pill](https://reader035.vdocument.in/reader035/viewer/2022062304/56812bd4550346895d90389f/html5/thumbnails/1.jpg)
The Universal PillThe Universal Pill
IGEM Presentation 17th July 09
James FieldDineka KhurmiNuri PurswaniKun Xue
![Page 2: The Universal Pill](https://reader035.vdocument.in/reader035/viewer/2022062304/56812bd4550346895d90389f/html5/thumbnails/2.jpg)
Project DescriptionProject Description
Specification Design Modelling Implementation Testing/Validation
Problem for oral delivery of peptides
• 1 pill = 1 drug
• High manufacturing cost
• Variable peptide half life
Solution…
• User defined drug production…
![Page 3: The Universal Pill](https://reader035.vdocument.in/reader035/viewer/2022062304/56812bd4550346895d90389f/html5/thumbnails/3.jpg)
The Universal PillThe Universal Pill
Specification Design Modelling Implementation Testing/Validation
• Multiple inputs enable drug selection
• Offers uniformity
• Direct packaging
• Fresh peptide production
• Dosage control
• Reduced loss of peptide
Capsule
Bacteria
![Page 4: The Universal Pill](https://reader035.vdocument.in/reader035/viewer/2022062304/56812bd4550346895d90389f/html5/thumbnails/4.jpg)
Current MethodsCurrent Methods
Specification Design Modelling Implementation Testing/Validation
Peptide delivery Basic Mechanism Main Advantages Main DisadvantagesPolysaccharides Hydrogel
encapsulation- Safe- Biodegradable
- Hard to encapsulate peptides
Polyethylene glycol (PEG)
Conjugates to proteins forming amphiphilic complex
- Proteins not denatured- Can cross mucosa
- May alter biological function of protein
Liposomes Phospholipid bilayer carriers
- Targeting - Manufacturing
Symbiotic Microbe Secretion - Sustained drug production- Multiple drug outputs
- Difficult to regulate
![Page 5: The Universal Pill](https://reader035.vdocument.in/reader035/viewer/2022062304/56812bd4550346895d90389f/html5/thumbnails/5.jpg)
Integrated SolutionIntegrated Solution
Specification Design Modelling Implementation Testing/Validation
Peptide delivery Basic Mechanism Main Advantages Main DisadvantagesPolysaccharides Hydrogel
encapsulation- Safe- Biodegradable
- Hard to encapsulate peptides
Polyethylene glycol (PEG)
Conjugates to proteins forming amphiphilic complex
- Proteins not denatured- Can cross mucosa
- May alter biological function of protein
Liposomes Phospholipid bilayer carriers
- Targeting - Manufacturing
Symbiotic Microbe Secretion - Sustained drug production- Multiple drug outputs
- Difficult to regulate
![Page 6: The Universal Pill](https://reader035.vdocument.in/reader035/viewer/2022062304/56812bd4550346895d90389f/html5/thumbnails/6.jpg)
Chosen SolutionChosen Solution
Specification Design Modelling Implementation Testing/Validation
Polysaccharide encapsulation of chassis
Combining polysaccharide & symbiotic microbe delivery offers the following advantages:
• Synthesis on demand without risk of GMO
• Protein is not denatured during storage & transport
Capsule
Bacteria
![Page 7: The Universal Pill](https://reader035.vdocument.in/reader035/viewer/2022062304/56812bd4550346895d90389f/html5/thumbnails/7.jpg)
Specification Design Modelling Implementation Testing/Validation
Encapsulate
Express
Kill
Release
Mechanism OverviewMechanism Overview• Polysaccharide encapsulation of chassis.• Peptide synthesis prior to consumption.
![Page 8: The Universal Pill](https://reader035.vdocument.in/reader035/viewer/2022062304/56812bd4550346895d90389f/html5/thumbnails/8.jpg)
Light Trigger Logic CircuitLight Trigger Logic Circuit
Specification Design Modelling Implementation Testing/Validation
Drug 1
0
0
B
R
R = 0B = 0
R = 0B = 1
R = 1B = 0
R = 1B = 1
No production
Drug 1
Drug 2
Drug 3
Drug 2
Drug 3
![Page 9: The Universal Pill](https://reader035.vdocument.in/reader035/viewer/2022062304/56812bd4550346895d90389f/html5/thumbnails/9.jpg)
Proposed ApplicationsProposed ApplicationsDisease General description Treatment drug Description
Diabetes Mellitus
Inability to metabolize glucose.
- GLP-1 Insulin production Glucagon production Beta cell mass and insulin gene expression Acid secretion and gastric emptying in the stomach Food intake by hunger
Haemophilia Hereditary disorder impairing body’s ability to control blood clotting or coagulation.
- Factor VIII in haemophilia A - Factor IX in haemophilia B
- Co-factor associated in the blood clotting cascade mechanism
Hay fever Allergic rhinitis frequently caused by pollen.
- Antigen - Reduces allergic reaction symptoms
![Page 10: The Universal Pill](https://reader035.vdocument.in/reader035/viewer/2022062304/56812bd4550346895d90389f/html5/thumbnails/10.jpg)
Chassis CriteriaChassis Criteria
Testing/Validation
• Non pathogenic strain
• Large Biobrick availability
• Expertise in college
• Freeze dry
![Page 11: The Universal Pill](https://reader035.vdocument.in/reader035/viewer/2022062304/56812bd4550346895d90389f/html5/thumbnails/11.jpg)
Chassis considerationsConsiderations
Chassis Non –pathogenic
Large bio-brickavailability
ExpertiseIncollege
Freeze dry
E.coli Yes Large Yes (most)
50% survival
B.subtilis Yes Few Yes est. 80% survival
S.cerevisiae Yes few Yes 10% survival
![Page 12: The Universal Pill](https://reader035.vdocument.in/reader035/viewer/2022062304/56812bd4550346895d90389f/html5/thumbnails/12.jpg)
Capsule Design Capsule Design OverviewOverview
1) Encapsulation
2) Storage
3) Protein expression
4) Acid resistance
5) Release
![Page 13: The Universal Pill](https://reader035.vdocument.in/reader035/viewer/2022062304/56812bd4550346895d90389f/html5/thumbnails/13.jpg)
1) Encapsulation1) Encapsulation
• enhances cell resistance to freezing and freeze-drying (for storage)
• added convenience and reduced packaging costs
• longer stability and viability during storage
![Page 14: The Universal Pill](https://reader035.vdocument.in/reader035/viewer/2022062304/56812bd4550346895d90389f/html5/thumbnails/14.jpg)
Cell Encapsulation method
Mechanism Advantages Disadvantages
Alginate hydrogels
Sodium alginate forms solid gel with Ca2+
-mild-low cost
-leaking (for pure alginate)
Spray coating of fats
Dissolved in polymer and trapped in dried particle
- short contact time, good for labile particles
- Must be heat resistant for spray-dry encapsulation
Rennet- Gelling
Milk proteins form gels upon Rennet action
-milk is common food item
-storage problem
Encapsulation Method Encapsulation Method ComparisonComparison
![Page 15: The Universal Pill](https://reader035.vdocument.in/reader035/viewer/2022062304/56812bd4550346895d90389f/html5/thumbnails/15.jpg)
Encapsulation detailsEncapsulation details
An in situ method for cultivating microorganisms using a double encapsulation techniqueEitan Ben-Dov1,2, Esti Kramarsky-Winter3,4 & Ariel Kushmaro1,5
![Page 16: The Universal Pill](https://reader035.vdocument.in/reader035/viewer/2022062304/56812bd4550346895d90389f/html5/thumbnails/16.jpg)
2) Storage2) StorageShort term storage-up to a monthNutrient agarKeep in a sealable containerStorage in refrigerator
Long term storageInclusion of glycerol storage in freeze-dried formfreeze at -20°C or -80°C
![Page 17: The Universal Pill](https://reader035.vdocument.in/reader035/viewer/2022062304/56812bd4550346895d90389f/html5/thumbnails/17.jpg)
Freeze drying
![Page 18: The Universal Pill](https://reader035.vdocument.in/reader035/viewer/2022062304/56812bd4550346895d90389f/html5/thumbnails/18.jpg)
3) Protein expression
Transparency to light important for light inputs reaching cells
Alginate is transparent
Transparency type nutrient agar
![Page 19: The Universal Pill](https://reader035.vdocument.in/reader035/viewer/2022062304/56812bd4550346895d90389f/html5/thumbnails/19.jpg)
Protein DepositionProtein Deposition
Proteins expressed are exported from the cell into the nutrient agar
Proteins stored in pores of nutrient agar until release
![Page 20: The Universal Pill](https://reader035.vdocument.in/reader035/viewer/2022062304/56812bd4550346895d90389f/html5/thumbnails/20.jpg)
Exposure of bifidobacteria to simulated gastric juice at pH 2.0
Diameters of 40–80 μm - insignificant protection
1–3 mm - microspheres protected
entrapped cellsEncapsulation in alginate-coated gelatin microspheres improves survival of the probiotic Bifidobacterium adolescentis 15703T during exposure to simulated gastro-intestinal conditions
N.T. Annana, A.D. Borzaa and L. Truelstrup Hansen
4) Resistance to stomach 4) Resistance to stomach acidityacidity
![Page 21: The Universal Pill](https://reader035.vdocument.in/reader035/viewer/2022062304/56812bd4550346895d90389f/html5/thumbnails/21.jpg)
When pH is lowered below the pKa values of d-mannuronic and l-guluronic acid (3.6 and 3.7, respectively), alginate is converted to alginic acid with release of calcium ions
Stomach pH is at 1-3Disintegration times for alginate-
coating was 120 min
Resistance to AcidityResistance to Acidity
![Page 22: The Universal Pill](https://reader035.vdocument.in/reader035/viewer/2022062304/56812bd4550346895d90389f/html5/thumbnails/22.jpg)
5) Release
Full degradation of alginate coat in intestines
Protein in nutrient agar now released
![Page 23: The Universal Pill](https://reader035.vdocument.in/reader035/viewer/2022062304/56812bd4550346895d90389f/html5/thumbnails/23.jpg)
The Vision
LOAD PILLSELECT DRUGSELECT DOSECOMPETE
![Page 24: The Universal Pill](https://reader035.vdocument.in/reader035/viewer/2022062304/56812bd4550346895d90389f/html5/thumbnails/24.jpg)
Black Box
Light
Chemical
![Page 25: The Universal Pill](https://reader035.vdocument.in/reader035/viewer/2022062304/56812bd4550346895d90389f/html5/thumbnails/25.jpg)
BLACK BOX: Modules
Timer
Dose Control
Drug Control
Wavelength
Light Sensing
Peptide synthesis
Restriction enzyme
synthesis
Frequency
![Page 26: The Universal Pill](https://reader035.vdocument.in/reader035/viewer/2022062304/56812bd4550346895d90389f/html5/thumbnails/26.jpg)
INPUT: Encoding with Light
Wavelength: Pulse:
Time
1
0
Drug Choice Dosage
Cph8
YcgF/YcgE
![Page 27: The Universal Pill](https://reader035.vdocument.in/reader035/viewer/2022062304/56812bd4550346895d90389f/html5/thumbnails/27.jpg)
Wavelength Encoding
Output
Input
1, 0 1, 1 0, 1
A B C
![Page 28: The Universal Pill](https://reader035.vdocument.in/reader035/viewer/2022062304/56812bd4550346895d90389f/html5/thumbnails/28.jpg)
Genetic Simulation
A
B
C
COMMAND = ACTIVATE A
P1 G1 G2
P2 G3 G4
P3 G5 P4 G6
A
![Page 29: The Universal Pill](https://reader035.vdocument.in/reader035/viewer/2022062304/56812bd4550346895d90389f/html5/thumbnails/29.jpg)
Genetic Simulation
A
B
C
COMMAND = ACTIVATE B
P1 G1 G2
P2 G3 G4
P3 G5 P4 G6
B
![Page 30: The Universal Pill](https://reader035.vdocument.in/reader035/viewer/2022062304/56812bd4550346895d90389f/html5/thumbnails/30.jpg)
Genetic Simulation
A
B
C
COMMAND = ACTIVATE C
P1 G1 G2
P2 G3 G4
P3 G5 P4 G6
C
![Page 31: The Universal Pill](https://reader035.vdocument.in/reader035/viewer/2022062304/56812bd4550346895d90389f/html5/thumbnails/31.jpg)
Pulse Encoding
Output
Input
Time
1
0Time
1
0Time
1
0
![Page 32: The Universal Pill](https://reader035.vdocument.in/reader035/viewer/2022062304/56812bd4550346895d90389f/html5/thumbnails/32.jpg)
Excitable protein output
Specification Design Modelling Implementation Testing/Validation
Time
Protein
![Page 33: The Universal Pill](https://reader035.vdocument.in/reader035/viewer/2022062304/56812bd4550346895d90389f/html5/thumbnails/33.jpg)
Comparator Specifications1: Strong Biobrick characterisation.2: Precise relationship between
coexpressed drug and reporter group.3: Defined time in which to compute
required pulse frequency.
![Page 34: The Universal Pill](https://reader035.vdocument.in/reader035/viewer/2022062304/56812bd4550346895d90389f/html5/thumbnails/34.jpg)
Timer Specifications1: Responsive to 1st light pulse only.2: Restriction enzymes expressed at
end of time period.
Time
Protein
Threshold
![Page 35: The Universal Pill](https://reader035.vdocument.in/reader035/viewer/2022062304/56812bd4550346895d90389f/html5/thumbnails/35.jpg)
Operation Summary
Select desired drug
Light
Chemical
INPUT MODULATION
Select desired dosage COMPARATOR MODULATION
![Page 36: The Universal Pill](https://reader035.vdocument.in/reader035/viewer/2022062304/56812bd4550346895d90389f/html5/thumbnails/36.jpg)
Summary
Light Receptor
Wavelength Processing
Pulse Processing
Start Timer
Drug Synthesis
& Secretion
Threshold detector
Restriction Enzyme
Synthesis
![Page 37: The Universal Pill](https://reader035.vdocument.in/reader035/viewer/2022062304/56812bd4550346895d90389f/html5/thumbnails/37.jpg)
Modelling considerations: Modelling considerations: ComponentsComponents
Protein controlled timer:◦ Simple logic gate representations
Timer block:◦ Rate of protein expression and degradation (ETH
07)◦ Threshold mechanism: “Schmitt trigger” (Taipei
07)Encapsulation efficiency:
◦ Particle size, morphology, swelling (Martins et al 2007)
Metabolic considerations:◦ Behaviour of bacteria inside the capsule (Wen-
tao Qi et al. 2005)◦ Comparison with free in culture medium
![Page 38: The Universal Pill](https://reader035.vdocument.in/reader035/viewer/2022062304/56812bd4550346895d90389f/html5/thumbnails/38.jpg)
Model parametersModel parametersProtein controlled timer:
- Light absorbance, pigment formation: Directly indicative of amount of protein present?
Encapsulation efficiency:- Diffusion of drug through capsule
Metabolic considerations:- Bacterial growth rate, population
consumption
![Page 39: The Universal Pill](https://reader035.vdocument.in/reader035/viewer/2022062304/56812bd4550346895d90389f/html5/thumbnails/39.jpg)
Questions we would expect Questions we would expect our models to answerour models to answer
Protein controlled timer:- Obtain optimal input light conditions for
protein degradation. Encapsulation efficiency:
- Find out optimal dimensions for maximal diffusion of substances through capsule.
Metabolic considerations:- Find optimal nutrient agar composition
to obtain indication of bacterial survival.
![Page 40: The Universal Pill](https://reader035.vdocument.in/reader035/viewer/2022062304/56812bd4550346895d90389f/html5/thumbnails/40.jpg)
SummarySummarySolution:
User defined drug production for oral administration
• 1 pill = 1 drug
• High manufacturing cost
• Variable peptide half life